The new standalone company is worth up to 28 billion Swiss francs.
The new standalone company is worth up to 28 billion Swiss francs.
The new resource will help innovators navigate the confusing innovation pathway to access the NHS.
The drug is typically used with fulvestrant to treat people with advanced breast cancer.
The approval makes it the first PARP inhibitor approved in Europe for the disease.
One in two women will experience a fracture due to osteoporosis in their lifetime.
Whilst 58% of areas saw an increase in spending, a worrying 37% saw a real-term fall.
The funding totals £829,892 and will help to develop new disease modulating drugs.
The company did not submit certain non-clinical studies to allow the FDA to assess chronic administration of the drug.
The company kept the announcement short, but said the study did not meet its primary endpoint.
The patent further strengthens Verona Pharma’s intellectual property estate.
It marks the first two-drug complete regimen for HIV-infected patients.
Also mentioned were Eisai and MSD’s Lenvima and UCB’s Cimzia.
Pfizer’s Ibrance will now be available to male patients with metastatic breast cancer.
The facility will be based at CPI’s existing space at NETPark, County Durham.
The decision aid also says that all used inhalers should be returned to local pharmacies for environmentally safe disposal.